Erasca News and Activities
Presence
Erasca is a biotechnology company that develops cancer medicines and research services. Its products focus on targeted oncology treatments for patients, healthcare providers, and drug development partners.
Erasca products and services overview:
- Cancer therapies
- Targeted medicines
- Drug discovery
- Clinical development
Revenue: ~$0 million
Employees: 130
Headquarters: San Diego, United States (USA)
Erasca is one of the...
Erasca is a company listed under the stock ticker ERAS (US).
Executives
View the org chart displaying its 24 main executives
Most searched biographies at Erasca
- Jonathan Lim, Chairman of the Board and Chief Executive Officer
- Alexander Casdin, Director
- Jean Liu, Director
Create your alert
to follow the executive moves at Erasca.
Biotechnology
Erasca has 2,425 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- Chemomab and Scipher Medicine have announced they will merge (posted on July 13 2026)..
- Apnimed has filed its IPO. Its stock ticker will be APMD. (posted on July 13 2026).
- The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).
Popular contacts in Biotechnology
News
Press releases by Erasca
- Erasca to Present at the Jefferies Global Healthcare Conference – Erasca
- Erasca Reports First Quarter 2026 Business Updates and Financial Results – Erasca
- Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab) – Erasca
- Erasca to Present at the Bank of America Securities Health Care Conference – Erasca
- Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors – Erasca
- Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 – Erasca
- Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau – Erasca
- Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results – Erasca
- Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat – Erasca
- Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 – Erasca
- View more press releases Close
Social media about Erasca
- Erasca on Wikipedia, Google News & Yahoo Finance
- Erasca on LinkedIn, X (Twitter) & YouTube
